[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-214

All good and thanks. I am just your everyday shareholder.

Tillett asked if he could use some of the tables I created in a company prospectus a while ago - I believe he changed them a little. I was happy to share them, didn't receive anything for them, and would have humbly declined if I was offered anything for them. Just happy to feel as though I had helped.

I am clearly very active in this space and have a drive for understanding this company, so Daniel has answered many questions from me regarding Bisantrene and declined to answer MANY more, haha.

The natural next question might be why I publish material online. I sacrificed a lot for my Masters with the main things being time and money. Much like my current devotion to the game of golf and achieving scratch within 5-years, I have come to think of RAC as a long-term Masters project that is self-paced. There is short-term sacrifice for long-term benefit. I publish material online because it forces me to understand the data at a depth required to explain it in as simple terms as possible to a wide audience. Teaching something helps me solidify my own learning, streamlining my thinking to focus on exactly what matters which will continue to grow over time alongside more learnings from this journey.